Sanford-Burnham goes fourth
Sanford-Burnham Medical Research Institute's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader partnerships that tap both its basic research and drug discovery expertise. Its new deal with Daiichi Sankyo Co. Ltd. is its most expansive to date in terms of the range of projects and number of faculty members it will encompass.
Sanford-Burnham's expanding approach to industry partnerships contrasts with that of The Scripps Research Institute, which has moved away from the institute-wide agreements it had previously maintained with pharma.1,2
Under the three-year deal, Sanford-Burnham will conduct preclinical studies to identify and validate new cardiovascular and metabolic disease targets. Researchers from the institute and Daiichi Sankyo's Cardiovascular-Metabolics Research Laboratories will perform screening to identify new compounds against those